Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kuros BiosciencesCSBTF 72 Earnings Yield (Joel Greenblatt) % is 0.51% as of Dec. 2025. GuruFocus rates CSBTF with a GF Score™ of 72/100 and a GF Value™ of $51.20 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 50.99% on this metric.
Kuros Biosciences's Enterprise Value for the quarter that ended in Dec. 2025 was $1,479.1 Mil.
Kuros Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $6.6 Mil. Kuros Biosciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 0.51%.
The historical rank and industry rank for Kuros Biosciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CSBTF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3069.64 Med: -29.22 Max: 779
Current: 0.65
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Kuros Biosciences was 779.00%. The lowest was -3069.64%. And the median was -29.22%.
CSBTF's Earnings Yield (Joel Greenblatt) % is ranked worse than 50.99% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.81
vs CSBTF: 0.65
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Kuros Biosciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Kuros Biosciences (OTCPK:CSBTF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Kuros Biosciences Earnings Yield (Joel Greenblatt) % Related Terms
Kuros Biosciences Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences Earnings Yield (Joel Greenblatt) % Chart
For the Medical Devices subindustry, Kuros Biosciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Earnings Yield (Joel Greenblatt) % falls into.
Kuros Biosciences Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Kuros Biosciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 0.51% mean?
Kuros Biosciences (CSBTF) has a Earnings Yield (Joel Greenblatt) % of 0.51% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #436 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 51%.
Is Kuros Biosciences' Earnings Yield (Joel Greenblatt) % too high?
Kuros Biosciences' current Earnings Yield (Joel Greenblatt) % is 0.51%. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.81. Kuros Biosciences' value of 0.51% is 37% below this industry median. Based on the distribution chart, Kuros Biosciences ranks #436 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Earnings Yield (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #436 out of 855 companies for Earnings Yield (Joel Greenblatt) %. This places Kuros Biosciences in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.81. Kuros Biosciences' value of 0.51% is 37% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.81, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Earnings Yield (Joel Greenblatt) % of 0.51% is 37% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Earnings Yield (Joel Greenblatt) % is 0.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $51.20, compared to a current price of $25.57 — trading 50.1% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.51% and 37% below the Medical Devices & Instruments industry median of 0.81. Kuros Biosciences' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Earnings Yield (Joel Greenblatt) % is 0.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $25.57 is trading 50.1% below its estimated GF Value™ of $51.20.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Earnings Yield (Joel Greenblatt) %: 0.51%
GF Value™: $51.20 vs. price of $25.57 (50.1% below fair value)
Industry Position: 37% below the Medical Devices & Instruments median (#436 of 855)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
72GF Score
Get the complete analysis for CSBTF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
